lysakare
advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - sugárzás sérülések - detoxifying agents for antineoplastic treatment - lysakare javallt csökkentése, a vese, a sugárzás során peptid-receptor radionuklid terápia (tette) a lutetium (177lu) oxodotreotide felnőttek.
somakit toc
advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - diagnosztikai radiofarmakonok - ez a gyógyszer csak diagnosztikai célra használható. a radioaktív jelölést követően a gallium (68ga) - klorid-oldatot, a megoldás a gallium (68ga) edotreotide kapott javallt pozitron emissziós tomográfia (pet) képalkotó szomatosztatin receptor fokozott a felnőtt betegek megerősített vagy gyanús jól differenciált gyomor-enteropancreatic neuroendokrin tumorok (gep-net) honosítása elsődleges daganatok, valamint az áttétek.
cuprymina
a.c.o.m. - advanced center oncology - réz (64cu) -kloridot - radionuklid képalkotás - various diagnostic radiopharmaceuticals - a cuprymina egy radiofarmakológiai prekurzor. nem alkalmas a betegek közvetlen használatra. a gyógyszer kell használni csak a szállító molekulák, amelyekből különösen fejlett, és engedélyezett a radioizotópos e radionuklid radioizotópos.
yuup advanced professional eye contour cleanser
g.r. kereskedelmi és szolgáltató bt. - külsoleges oldat - kutya
lonsurf
les laboratoires servier - trifluridine, tipiracil-hidroklorid - colorectalis daganatok - daganatellenes szerek - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
lutathera
advanced accelerator applications - lutetium (177lu) -oxodotreotid - neuroendokrin tumorok - egyéb terápiás radiofarmakonok - lutathera javallt a kezelés az inoperábilis vagy áttétes, progresszív, jól differenciált (g1 és g2), szomatosztatin receptor pozitív gastroenteropancreatic neuroendokrin daganatok (gep‑nets) a felnőttek.
firmagon
ferring pharmaceuticals a/s - degarelixet - prosztatikus daganatok - endokrin terápia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
rekovelle
ferring pharmaceuticals a/s - follitropin delta - anovulációja - nemi hormonok pedig veheti a nemi rendszer, - irányított a kialakulását nők átesett asszisztált reprodukciós technológiák (art) például egy in vitro fertilizáció (ivf) és az intracitoplazmatikus spermium injekció (icsi) ciklus több tüszők a petefészek stimuláció.
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanóma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - daganatellenes szerek - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.